The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats
Open Access
- 17 August 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (8), e43433
- https://doi.org/10.1371/journal.pone.0043433
Abstract
The nitric oxide (NO)–soluble guanylate cyclase (sGC)–cyclic guanosine monophosphate (cGMP) signal-transduction pathway is impaired in many cardiovascular diseases, including pulmonary arterial hypertension (PAH). Riociguat (BAY 63–2521) is a stimulator of sGC that works both in synergy with and independently of NO to increase levels of cGMP. The aims of this study were to investigate the role of NO–sGC–cGMP signaling in a model of severe PAH and to evaluate the effects of sGC stimulation by riociguat and PDE5 inhibition by sildenafil on pulmonary hemodynamics and vascular remodeling in severe experimental PAH. Severe angioproliferative PAH was induced in rats by combined exposure to the vascular endothelial growth factor receptor antagonist SU5416 and hypoxia (SUHx). Twenty-one days thereafter rats were randomized to receive either riociguat (10 mg/kg/day), sildenafil (50 mg/kg/day) or vehicle by oral gavage, for 14 days until the day of the terminal hemodynamic measurements. Administration of riociguat or sildenafil significantly decreased right ventricular systolic pressure (RVSP). Riociguat significantly decreased RV hypertrophy (RVH) (0.55±0.02, pp−1 ml−1 100 g BW, pppp<0.05). Riociguat and sildenafil significantly reduced RVSP and RVH, and improved RV function compared with vehicle. Riociguat had a greater effect on hemodynamics and RVH than sildenafil.This publication has 41 references indexed in Scilit:
- Copper Dependence of Angioproliferation in Pulmonary Arterial Hypertension in Rats and HumansAmerican Journal of Respiratory Cell and Molecular Biology, 2012
- Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertensionRespiratory Research, 2011
- Soluble Guanylate Cyclase Stimulation Prevents Fibrotic Tissue Remodeling and Improves Survival in Salt-Sensitive Dahl RatsPLOS ONE, 2011
- Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in experimental pulmonary hypertensionAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2010
- Cellular and Molecular Basis of Pulmonary Arterial HypertensionJournal of the American College of Cardiology, 2009
- First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertensionEuropean Respiratory Journal, 2009
- Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vesselsJCI Insight, 2006
- Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular RemodelingCirculation, 2006
- Antiremodeling Effects of Iloprost and the Dual-Selective Phosphodiesterase 3/4 Inhibitor Tolafentrine in Chronic Experimental Pulmonary HypertensionCirculation Research, 2004
- Noninvasive evaluation of pulmonary hypertension by a pulsed Doppler technique.Circulation, 1983